In Brief: Medtronic InSync
This article was originally published in The Gray Sheet
Executive Summary
Medtronic InSync: Bi-ventricular cardiac stimulator for treament of congestive heart failure is "moving into the clinical trial phase in the U.S.," company Chairman and CEO William George tells investors at a Feb. 3 session of the Piper Jaffray medical device conference in New York City. The device, which paces both sides of the heart through a proprietary transvenous lead system, "is progressing quickly through its initial 60-patient human clinical in Europe as well as in Canada," George notes, adding that "the greatest long-term opportunity for Medtronic in the pacing business is the treatment of congestive heart failure with biventricular cardiac stimulation" technology...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.